Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself.Academy: 200-day line · RSI
About the company
Medtronic is a medical technology company based in Ireland. It makes pacemakers, heart valves, insulin pumps, spinal implants, neurostimulators and surgical instruments. The diabetes division is to be separated. As of Oct 13, 2026
As of Oct 13, 2026Fact sheet (from the annual report)Electromedical equipment · Galwayfull fact sheet
Medtronic, based in Galway, Ireland, serves health systems, physicians, clinicians and patients. The Cardiovascular Portfolio, Neuroscience Portfolio and Medical Surgical Portfolio segments develop, manufacture and sell mainly device-based therapies and services. In cardiology, the offering includes pacemakers, products for atrial fibrillation and products for heart valve repair and replacement. Neuroscience comprises navigation and robotic systems for spine and cranial procedures, spinal implants and stroke products. The Medical Surgical Portfolio is aimed mainly at health systems, physician offices and ambulatory surgery centers. In March 2026 the MiniMed diabetes division completed an initial public offering, and in the final quarter of fiscal year 2026 diabetes was no longer a reportable segment.
Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.
Detected chart patterns
Inverse head and shoulders on the weekly chart, detected in the week of Oct 12, 2026
Free with an account until Jan 31, 2027: all Premium features, no subscription and no card. Sign up free
Earlier patterns · Past performance, not a forecast
Earlier patternsChart patterns that were detected for this asset earlier, each with its outcome: target 1 reached, stop reached (invalid), time limit over or still open. A list of the past, not a forecast.Example: Example: “Flag, detected on 3 Sep, target 1 reached on 22 Sep” – describes that one case, not the next pattern.More in the Academy: Glossary
Trend by timeframeFor each timeframe (week, day, 4 hours): up when the close is above the SMA 200, the EMA 20 above the EMA 50 and the structure shows higher highs and lows. Down the other way round, otherwise mixed. No score, no forecast.Example: Week up, day up, 4 hours mixed → not aligned.More in the Academy: Lesson trend and market structure
1Wweekly candles↗ up
Close above the SMA 200
EMA 20 above the EMA 50
higher highs and higher lows
Price above the EMA 20 · above the EMA 50
Week to Nov 20, 2026
1Ddaily candles↔ mixed
Close above the SMA 200
EMA 20 above the EMA 50
Highs and lows mixed
Price above the EMA 20 · above the EMA 50
Daily candle of Nov 20, 2026
4H4-hour candles↔ mixed
Close above the SMA 200
EMA 20 above the EMA 50
lower highs and lower lows
Price below the EMA 20 · above the EMA 50
Candle from Nov 20, 2026, 19:30
Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up →
What does the daily chart show right now – line by line, without an overall verdict?
Technicals in plain words
Technicals in plain wordsFour lines on the daily chart – trend, momentum, volume, volatility –, each with its metric and threshold. We do not add the lines up or give a grade; they describe the price history so far.Example: RSI 64 → between 30 and 70, neither overbought nor oversold.More in the Academy: Lesson reading the RSI
Over the last 3 months it ran stronger than the S&P 500 and stronger than the median of the sector “Health Care”.
vs. S&P 500 · 3 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
vs. S&P 500 · 6 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
vs. sector · 3 monthsRelative strengthA stock’s price change minus that of the benchmark over the same period, in percentage points: against the S&P 500 (ETF SPY) or the median of its sector, over 3 or 6 months. Above 0 it ran stronger, below 0 weaker – this describes the past.Example: Stock +12%, S&P 500 +5% in 3 months → +7 percentage points, ran stronger.More in the Academy: Lesson relative strength
stronger
Trendabove SMA 200Price above the 200-day line – above it the long-term trend counts as up; ADX above 25 – a pronounced trend.
MomentumneutralRSI between 30 and 70 – neither overbought nor oversold; MACD line fell below its signal line in the last 5 trading days.
Volumenot elevatedVolume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
VolatilitynormalTypical daily range (ATR 14) between 2 and 4% of the price – normal.
The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account.Sign up free
More depth
How we read the lines
Each line stands on its own – we do not add them up and give no grade.
Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
Against the sector median over 6 months: ran stronger.
All figures describe the price history so far – they do not say what happens next.
As of: daily candle of Nov 20, 2026 · from our daily candles
How did this asset do in each calendar month over the last 10 years?
Seasonality
SeasonalityHow an asset did in each calendar month over the last 10 years: monthly return from the last trading day of the previous month to the last one of the month, without dividends, completed months only. Past performance, not a forecast.Example: Example: November higher in 7 of 10 years → describes past years, not the next November.More in the Academy: Lesson seasonality
In November, the stock closed higher in 6 of 10 years – the S&P 500 in 9 of 10.
Years higher in NovemberSeasonalityHow an asset did in each calendar month over the last 10 years: monthly return from the last trading day of the previous month to the last one of the month, without dividends, completed months only. Past performance, not a forecast.Example: Example: November higher in 7 of 10 years → describes past years, not the next November.More in the Academy: Lesson seasonality
6 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
4 of 12
Calendar months that closed higher in more than half of the years
You can see the median and range per month in percent with a free account.Sign up free
7/10Jan
5/10Feb
5/10Mar
4/10Apr
5/10May
5/10Jun
8/10Jul
7/10Aug
4/10Sep
4/10Oct
6/10Nov
3/10Dec
January: higher in 7 of 10 years
February: higher in 5 of 10 years
March: higher in 5 of 10 years
April: higher in 4 of 10 years
May: higher in 5 of 10 years
June: higher in 5 of 10 years
July: higher in 8 of 10 years
August: higher in 7 of 10 years
September: higher in 4 of 10 years
October: higher in 4 of 10 years
November (current month): higher in 6 of 10 years
December: higher in 3 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividendsMore depth
How we calculate
Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
Month
Years higher
January
7 of 10
February
5 of 10
March
5 of 10
April
4 of 10
May
5 of 10
June
5 of 10
July
8 of 10
August
7 of 10
September
4 of 10
October
4 of 10
November ●
6 of 10
December
3 of 10
Through October 2026 (last completed month) · from our daily candles
Opportunity at a glance Medtronic
There is no opportunity card on 1-hour candles: we calculate patterns, targets and supports on the 4H, daily and weekly charts.
Pattern on the chart:Inverse head and shoulders on the weekly chart, detected in the week of Oct 12, 2026 – Entry area, stop and targets are calculated. You see these and all other figures on the card with a free account.
Quarterly results in 2 days (Nov 24, 2026) – prices can jump sharply.
What does this mean? The card sums up patterns, potential, risk and supports on the 4H, daily and weekly chart.
Potential to target 1●● %hidden4-hour or daily chart
Risk to stop
●● %hidden
Reward/risk
● : 1hidden
Remaining potential: moved since detection and still open to target 1 – each in % with timeframe.
Potential to target on the weekly chart●● %hiddenWeekly chart
Invalid below (weekly close)
●● %hidden
Supports below
3
Supports below with distance in %, timeframe and number of tests (possible levels to add).
Trend Trend by timeframeFor each timeframe (week, day, 4 hours): up when the close is above the SMA 200, the EMA 20 above the EMA 50 and the structure shows higher highs and lows. Down the other way round, otherwise mixed. No score, no forecast.Example: Week up, day up, 4 hours mixed → not aligned.More in the Academy: Lesson trend and market structure4H↔ mixed1D↔ mixed1W↗ up
In favour1 · Against0Points without chart-pattern detail – you see every point with figure and date with a free account
Calculated automatically by fixed rules – not investment advice. How we analyze
Potential
This shows the distance from the last close to the pattern’s target mark – a distance, not a return. Next to it the risk to the stop, each with the timeframe the figure comes from.
Supports below
Under “Long term” you find price areas below the price where it has already turned several times – with distance in percent, timeframe and number of tests. They describe where the price found support before.
For · Against
Fixed rules collect facts that speak for or against the picture, each with its date. There is deliberately no total and no grade – you do the weighing yourself.
My plan
“My plan” remembers your holding period and a target level of your own and lets you know when the price reaches the entry area. That and all figures of the card are available with a free account.
Fundamental analysis
SEC filing (10-K, 10-Q)Required reports of listed companies to the US Securities and Exchange Commission (SEC): 10-K is the annual report, 10-Q the quarterly report, 20-F the annual report of foreign companies. We show the figures of the first filing.Example: 10-K for the fiscal year ending Sep 27, 2025, filed on Oct 31, 2025.More in the Academy: Lesson revenue, profit and margin
Medtronic · Sector Health Care · amounts in USD
Source: SEC filings, As of Jun 18, 2026.
Investor typeInvestor type (“lens”)You choose which style comes first: dividends, valuation, growth, quality or trading. Screener and stock page then show suggestions and “For you first”, with an account also matching columns and order. The lens unlocks nothing and changes no matches.Example: Lens “Dividends” → on the stock page first the streak without a cut, growth and cover of the dividend.More in the Academy: Guide fundamental analysis
For you firstDividend
The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 1.5x.
Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.
✓met: Profit in each of the last 5 fiscal years5 of 5
✓met: Free cash flow positive in each of the last 3 fiscal years3 of 3
✓met: Equity ratio above 30%53.2%
Gross margin
65.0%Fiscal year 2026
All75strong
Rank 75 of 100: higher than 75% of 370 peers (All). strong.
Sector54medium
Rank 54 of 100: higher than 54% of 49 peers (Sector). medium.
Median Health Care: 61.8%
Share of revenue left after the direct cost of the products sold.
Operating margin
17.8%Fiscal year 2026
All56medium
Rank 56 of 100: higher than 56% of 470 peers (All). medium.
Sector55medium
Rank 55 of 100: higher than 55% of 54 peers (Sector). medium.
Median Health Care: 17.0%
Operating income divided by revenue: what the core business earns before interest and taxes.
Net margin
13.2%Fiscal year 2026
All57medium
Rank 57 of 100: higher than 57% of 584 peers (All). medium.
Sector55medium
Rank 55 of 100: higher than 55% of 63 peers (Sector). medium.
Median Health Care: 12.9%
Profit after all costs, interest and taxes divided by revenue.
Return on equity
9.7%Fiscal year 2026
All36medium
Rank 36 of 100: higher than 36% of 544 peers (All). medium.
Sector31weak
Rank 31 of 100: higher than 31% of 54 peers (Sector). weak.
Median Health Care: 12.8%
Net income divided by equity at fiscal year end.
Return on assets
5.2%Fiscal year 2026 (total assets at year end)
All51medium
Rank 51 of 100: higher than 51% of 594 peers (All). medium.
Sector42medium
Rank 42 of 100: higher than 42% of 63 peers (Sector). medium.
Median Health Care: 6.6%
Net income divided by total assets at fiscal year end.
Equity ratio
53.2%Fiscal year 2026
All75strong
Rank 75 of 100: higher than 75% of 595 peers (All). strong.
Sector67strong
Rank 67 of 100: higher than 67% of 63 peers (Sector). strong.
Median Health Care: 44.2%
Equity as a share of total assets. Usually low for banks.
Free cash flow margin
14.9%Fiscal year 2026
All60medium
Rank 60 of 100: higher than 60% of 465 peers (All). medium.
Sector52medium
Rank 52 of 100: higher than 52% of 61 peers (Sector). medium.
Median Health Care: 14.5%
Free cash flow divided by revenue.
Free cash flow
5.4B USDFiscal year 2026
Operating cash flow minus capital expenditure on property and equipment.
Growth 5 of 7 met
✓met: Over 3 years, revenue grew by more than 5% per year+5.2%
✗not met: Over 5 years, revenue grew by more than 5% per year+3.8%
✗not met: Over 10 years, revenue grew by more than 5% per year+2.3%
✓met: Over 3 years, EPS grew by more than 5% per year+9.8%
✓met: Over 5 years, EPS grew by more than 5% per year+7.0%
✓met: Revenue rose in at least 4 of the last 5 fiscal years4 of 5
✓met: Revenue rose in the last fiscal year+8.4%
Revenue growth 3 years
+5.2%per year
All45medium
Rank 45 of 100: higher than 45% of 578 peers (All). medium.
Sector51medium
Rank 51 of 100: higher than 51% of 62 peers (Sector). medium.
Median Health Care: +5.1%
Average growth per year over 3 fiscal years.
Revenue growth 5 years
+3.8%per year
All20weak
Rank 20 of 100: higher than 20% of 549 peers (All). weak.
Sector21weak
Rank 21 of 100: higher than 21% of 60 peers (Sector). weak.
Median Health Care: +7.8%
Average growth per year over 5 fiscal years.
Revenue growth 10 years
+2.3%per year
All18weak
Rank 18 of 100: higher than 18% of 412 peers (All). weak.
Sector11weak
Rank 11 of 100: higher than 11% of 50 peers (Sector). weak.
Median Health Care: +9.3%
Average growth per year over 10 fiscal years.
EPS growth 3 years
+9.8%per year
All54medium
Rank 54 of 100: higher than 54% of 437 peers (All). medium.
Sector60medium
Rank 60 of 100: higher than 60% of 54 peers (Sector). medium.
Median Health Care: +5.0%
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 5 years
+7.0%per year
All33medium
Rank 33 of 100: higher than 33% of 399 peers (All). medium.
Sector44medium
Rank 44 of 100: higher than 44% of 47 peers (Sector). medium.
Median Health Care: +8.3%
Growth of earnings per share per year, adjusted for stock splits.
EPS growth 10 years
+4.2%per year
All24weak
Rank 24 of 100: higher than 24% of 375 peers (All). weak.
Sector23weak
Rank 23 of 100: higher than 23% of 46 peers (Sector). weak.
Median Health Care: +9.3%
Growth of earnings per share per year, adjusted for stock splits.
Dividend 6 of 7 met
✓met: Pays a dividend2.84 USD
✗not met: Payout ratio at most 60% of earnings76%
✓met: Dividend paid in each of the last 5 fiscal years5 of 5
✓met: Dividend per share never lowered in the last 5 fiscal yearsDividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut.never
✓met: Dividend per share higher than 5 years ago+4.1%
✓met: Free cash flow per share covers the dividend1.5x
✓met: Dividends paid over the last 5 years covered by free cash flow68% of free cash flow
Payout ratio
76%Fiscal year 2026
Dividend per share divided by earnings per share.
Dividend growth 5 years
+4.1%per year
All26weak
Rank 26 of 100: higher than 26% of 321 peers (All). weak.
Sector24weak
Rank 24 of 100: higher than 24% of 31 peers (Sector). weak.
Median Health Care: +6.6%
Growth of the dividend per share per year.
Free cash flow coverage
1.5xFiscal year 2026
Free cash flow per share divided by dividend per share. From 1x the dividend is covered.
Financial strength 6 of 6 met
✓met: Piotroski F-Score at least 7 of 97 of 9
✓met: Long-term debt no higher than equity0.53
✓met: Current assets cover current liabilities2.13
✓met: Positive equity49.5B USD
✓met: In 5 years, share count up by at most 5%−4.9%
✓met: Free cash flow positive in the last fiscal year5.4B USD
Piotroski F-Score
7 of 9Fiscal year 2026
All69strong
Rank 69 of 100: higher than 69% of 310 peers (All). strong.
Sector65medium
Rank 65 of 100: higher than 65% of 47 peers (Sector). medium.
Median Health Care: 6.0 of 9
Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.
Debt / equity
0.53at fiscal year end
All60medium
Rank 60 of 100: lower than 60% of 486 peers (All). medium.
Sector61medium
Rank 61 of 100: lower than 61% of 50 peers (Sector). medium.
Median Health Care: 0.66
Long-term financial debt divided by equity.
Liquidity (current ratio)
2.13at fiscal year end
All76strong
Rank 76 of 100: higher than 76% of 513 peers (All). strong.
Sector72strong
Rank 72 of 100: higher than 72% of 63 peers (Sector). strong.
Median Health Care: 1.58
Current assets divided by current liabilities.
Change in share count
−4.9%in 5 years
All57medium
Rank 57 of 100: lower than 57% of 507 peers (All). medium.
Sector53medium
Rank 53 of 100: lower than 53% of 59 peers (Sector). medium.
Median Health Care: −4.3%
Change in diluted share count. Negative = share buybacks, positive = new shares.
The 9 criteria of the Piotroski F-Score
✓met: Profit in the last fiscal year (positive return on assets)
✓met: Positive operating cash flow
✓met: Return on assets higher than the prior year
✓met: Operating cash flow higher than net income
✗not met: Long-term debt relative to total assets fell
✓met: Liquidity (current assets / current liabilities) rose
✓met: No additional shares (diluted share count did not rise)
✗not met: Gross margin higher than the prior year
✓met: Revenue relative to total assets higher than the prior year
Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.
Price-based criteria (P/E, dividend yield) are shown to signed-in users.
Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.
In short
Light yellow: Revenue grew over 5 years (+3.8% per year), more slowly than the sector median.
Light green: Net income (total) grew over 5 years (+5.9% per year), at least as fast as the sector median; per share +7.0% per year.
Light yellow: Net margin 13.2%, below the sector median (13.9%).
Light green: Debt not higher than usual in the sector.
Light green: Profit in each of the last 10 fiscal years.
Light yellow: High payout ratio (76% of earnings).
Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.
RevenueNet incomeNet margin (below)in USD
010B20B30B40B
2017Fiscal year 2017 (Apr 30, 2016 – Apr 28, 2017): Revenue 29.7B USD · Net income 4.0B USD · Net margin 13.6%
2018Fiscal year 2018 (Apr 29, 2017 – Apr 27, 2018): Revenue 30.0B USD · Net income 3.1B USD · Net margin 10.4%
2019Fiscal year 2019 (Apr 28, 2018 – Apr 26, 2019): Revenue 30.6B USD · Net income 4.6B USD · Net margin 15.2%
2020Fiscal year 2020 (Apr 27, 2019 – Apr 24, 2020): Revenue 28.9B USD · Net income 4.8B USD · Net margin 16.6%
2021Fiscal year 2021 (Apr 25, 2020 – Apr 30, 2021): Revenue 30.1B USD · Net income 3.6B USD · Net margin 12.0%
2022Fiscal year 2022 (May 1, 2021 – Apr 29, 2022): Revenue 31.7B USD · Net income 5.0B USD · Net margin 15.9%
2023Fiscal year 2023 (Apr 30, 2022 – Apr 28, 2023): Revenue 31.2B USD · Net income 3.8B USD · Net margin 12.0%
2024Fiscal year 2024 (Apr 29, 2023 – Apr 26, 2024): Revenue 32.4B USD · Net income 3.7B USD · Net margin 11.4%
2025Fiscal year 2025 (Apr 27, 2024 – Apr 25, 2025): Revenue 33.5B USD · Net income 4.7B USD · Net margin 13.9%
2026Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Revenue 36.4B USD · Net income 4.8B USD · Net margin 13.2%
Margin
14%10%15%17%12%16%12%11%14%13%
RevenueNet incomeNet margin (below)in USD
02.5B5B7.5B10B
Q4/23Quarter Q4/23 (Jul 29, 2023 – Oct 27, 2023): Revenue 8.0B USD · Net income 909.0M USD · Net margin 11.4%
Q1/24Quarter Q1/24 (Oct 28, 2023 – Jan 26, 2024): Revenue 8.1B USD · Net income 1.3B USD · Net margin 16.3%
Q2/24Quarter Q2/24 (Jan 27, 2024 – Apr 26, 2024): Revenue 8.6B USD · Net income 654.0M USD · Net margin 7.6% · Q4 derived (year minus 9 months), may be distorted by restatements
Q3/24Quarter Q3/24 (Apr 27, 2024 – Jul 26, 2024): Revenue 7.9B USD · Net income 1.0B USD · Net margin 13.2%
Q4/24Quarter Q4/24 (Jul 27, 2024 – Oct 25, 2024): Revenue 8.4B USD · Net income 1.3B USD · Net margin 15.1%
Q1/25Quarter Q1/25 (Oct 26, 2024 – Jan 24, 2025): Revenue 8.3B USD · Net income 1.3B USD · Net margin 15.6%
Q2/25Quarter Q2/25 (Jan 25, 2025 – Apr 25, 2025): Revenue 8.9B USD · Net income 1.1B USD · Net margin 11.8% · Q4 derived (year minus 9 months), may be distorted by restatements
Q3/25Quarter Q3/25 (Apr 26, 2025 – Jul 25, 2025): Revenue 8.6B USD · Net income 1.0B USD · Net margin 12.1%
Q4/25Quarter Q4/25 (Jul 26, 2025 – Oct 24, 2025): Revenue 9.0B USD · Net income 1.4B USD · Net margin 15.3%
Q1/26Quarter Q1/26 (Oct 25, 2025 – Jan 23, 2026): Revenue 9.0B USD · Net income 1.1B USD · Net margin 12.7%
Q2/26Quarter Q2/26 (Jan 24, 2026 – Apr 24, 2026): Revenue 9.8B USD · Net income 1.2B USD · Net margin 12.7% · Q4 derived (year minus 9 months), may be distorted by restatements
Q3/26Quarter Q3/26 (Apr 25, 2026 – Jul 31, 2026): Revenue 9.8B USD · Net income 1.5B USD · Net margin 15.1%
Margin
11%16%7.6%13%15%16%12%12%15%13%13%15%
Earnings per shareUSD per share
01.002.003.004.00
2017Fiscal year 2017 (Apr 30, 2016 – Apr 28, 2017): Earnings per share 2.89 USD
2018Fiscal year 2018 (Apr 29, 2017 – Apr 27, 2018): Earnings per share 2.27 USD
2019Fiscal year 2019 (Apr 28, 2018 – Apr 26, 2019): Earnings per share 3.41 USD
2020Fiscal year 2020 (Apr 27, 2019 – Apr 24, 2020): Earnings per share 3.54 USD
2021Fiscal year 2021 (Apr 25, 2020 – Apr 30, 2021): Earnings per share 2.66 USD
2022Fiscal year 2022 (May 1, 2021 – Apr 29, 2022): Earnings per share 3.73 USD
2023Fiscal year 2023 (Apr 30, 2022 – Apr 28, 2023): Earnings per share 2.82 USD
2024Fiscal year 2024 (Apr 29, 2023 – Apr 26, 2024): Earnings per share 2.76 USD
2025Fiscal year 2025 (Apr 27, 2024 – Apr 25, 2025): Earnings per share 3.61 USD
2026Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Earnings per share 3.73 USD
Earnings per shareUSD per share
00.501.001.50
Q4/23Quarter Q4/23 (Jul 29, 2023 – Oct 27, 2023): Earnings per share 0.68 USD
Q1/24Quarter Q1/24 (Oct 28, 2023 – Jan 26, 2024): Earnings per share 0.99 USD
Q2/24Quarter Q2/24 (Jan 27, 2024 – Apr 26, 2024): Earnings per share not reported separately for Q4
Dividend per sharePayout ratio (below)USD per share
01.002.003.00
2017Fiscal year 2017 (Apr 30, 2016 – Apr 28, 2017): Dividend per share 1.72 USD · Payout ratio 59.5%
2018Fiscal year 2018 (Apr 29, 2017 – Apr 27, 2018): Dividend per share 1.84 USD · Payout ratio 81.1%
2019Fiscal year 2019 (Apr 28, 2018 – Apr 26, 2019): Dividend per share 2.00 USD · Payout ratio 58.7%
2020Fiscal year 2020 (Apr 27, 2019 – Apr 24, 2020): Dividend per share 2.16 USD · Payout ratio 61.0%
2021Fiscal year 2021 (Apr 25, 2020 – Apr 30, 2021): Dividend per share 2.32 USD · Payout ratio 87.2%
2022Fiscal year 2022 (May 1, 2021 – Apr 29, 2022): Dividend per share 2.52 USD · Payout ratio 67.6%
2023Fiscal year 2023 (Apr 30, 2022 – Apr 28, 2023): Dividend per share 2.72 USD · Payout ratio 96.5%
2024Fiscal year 2024 (Apr 29, 2023 – Apr 26, 2024): Dividend per share 2.76 USD · Payout ratio 100.0%
2025Fiscal year 2025 (Apr 27, 2024 – Apr 25, 2025): Dividend per share 2.80 USD · Payout ratio 77.6%
2026Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Dividend per share 2.84 USD · Payout ratio 76.1%
Ratio
60%81%59%61%87%68%96%100%78%76%
Dividend per sharePayout ratio (below)USD per share
00.200.400.600.80
Q4/23Quarter Q4/23 (Jul 29, 2023 – Oct 27, 2023): Dividend per share 0.69 USD · Payout ratio 101.5%
Q1/24Quarter Q1/24 (Oct 28, 2023 – Jan 26, 2024): Dividend per share 0.69 USD · Payout ratio 69.7%
Q2/24Quarter Q2/24 (Jan 27, 2024 – Apr 26, 2024): Dividend per share not available · Payout ratio not available · Q4 derived (year minus 9 months), may be distorted by restatements
Q3/24Quarter Q3/24 (Apr 27, 2024 – Jul 26, 2024): Dividend per share 0.70 USD · Payout ratio 87.5%
Q4/24Quarter Q4/24 (Jul 27, 2024 – Oct 25, 2024): Dividend per share 0.70 USD · Payout ratio 70.7%
Q1/25Quarter Q1/25 (Oct 26, 2024 – Jan 24, 2025): Dividend per share 0.70 USD · Payout ratio 69.3%
Q2/25Quarter Q2/25 (Jan 25, 2025 – Apr 25, 2025): Dividend per share not available · Payout ratio not available · Q4 derived (year minus 9 months), may be distorted by restatements
Q3/25Quarter Q3/25 (Apr 26, 2025 – Jul 25, 2025): Dividend per share 0.71 USD · Payout ratio 87.7%
Q4/25Quarter Q4/25 (Jul 26, 2025 – Oct 24, 2025): Dividend per share 0.71 USD · Payout ratio 66.4%
Q1/26Quarter Q1/26 (Oct 25, 2025 – Jan 23, 2026): Dividend per share 0.71 USD · Payout ratio 79.8%
Q2/26Quarter Q2/26 (Jan 24, 2026 – Apr 24, 2026): Dividend per share not available · Payout ratio not available · Q4 derived (year minus 9 months), may be distorted by restatements
Q3/26Quarter Q3/26 (Apr 25, 2026 – Jul 31, 2026): Dividend per share 0.72 USD · Payout ratio 63.2%
Ratio
101%70%88%71%69%88%66%80%63%
Fiscal year 2026 (Apr 26, 2025 – Apr 24, 2026): Revenue 36.4B USD · Net income 4.8B USD · Net margin 13.2%
How has it gone since the last annual report?
Trailing 12 months and quarters
Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Revenue in the quarter to Jul 2026 +13.7% vs. the same quarter a year earlier; grown for 14 quarters in a row.
Revenue 12 months vs. prior 12Trailing 12 monthsFigures for the latest twelve months: fiscal year plus the months since it ended minus the same months a year earlier, each from the first SEC filing. More current than the fiscal year, but not audited. P/E, PEG and the checks still use the fiscal year.Example: Fiscal year $400M, 9 months after it $330M, same 9 months a year earlier $300M → 400 + 330 − 300 = $430M.More in the Academy: Lesson trailing twelve months
Free cash flow margin 12 monthsFree cash flowCash from operations minus investment in property, plant and equipment. It shows how much money is left over – for repaying debt, dividends or share repurchases.Example: Operating cash flow 120 million euros, investments 45 million euros → free cash flow 75 million euros.More in the Academy: Guide fundamental analysis
16.3%
Fiscal year 2026: 14.9%
More depth
Calculation of the 12 months to Jul 31, 2026
Revenue: fiscal year to Apr 24, 2026 36.4B USD + year to date to Jul 31, 2026 9.8B USD − same period a year earlier to Jul 25, 2025 8.6B USD = 37.5B USD
Net income: fiscal year to Apr 24, 2026 4.8B USD + year to date to Jul 31, 2026 1.5B USD − same period a year earlier to Jul 25, 2025 1.0B USD = 5.2B USD
Operating cash flow: fiscal year to Apr 24, 2026 7.3B USD + year to date to Jul 31, 2026 1.8B USD − same period a year earlier to Jul 25, 2025 1.1B USD = 8.0B USD
Capital expenditure: fiscal year to Apr 24, 2026 1.9B USD + year to date to Jul 31, 2026 503.0M USD − same period a year earlier to Jul 25, 2025 504.0M USD = 1.9B USD
By quarter (latest first, amounts in USD)
Quarter
Revenue
vs. year ago
Net income
Margin
May–Jul 26
9.8B
+13.7%
1.5B
15.1%
Jan–Apr 26*
9.8B
+9.9%
1.2B
12.7%
Nov 25–Jan 26
9.0B
+8.7%
1.1B
12.7%
Aug–Oct 25
9.0B
+6.6%
1.4B
15.3%
May–Jul 25
8.6B
+8.4%
1.0B
12.1%
Feb–Apr 25*
8.9B
+3.9%
1.1B
11.8%
Nov 24–Jan 25
8.3B
+2.5%
1.3B
15.6%
Aug–Oct 24
8.4B
+5.2%
1.3B
15.1%
Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.
Each quarter is compared with the same quarter a year earlier.
* derived: fiscal year minus the first 9 months.
As of: 12 months to Jul 31, 2026, filed on Sep 3, 2026 · Source: SEC filings (10-Q, 10-K)
Does the profit arrive as cash?
Earnings quality
Profit is backed by cash; interest is well covered.
Cash flow ÷ profitCash flow ÷ profitOperating cash flow divided by group profit. From 1.0, at least as much cash came in as profit was reported; below that, profit may sit in receivables or inventories, and non-cash gains or one-off payments also push the ratio down. Depreciation and stock-based pay lift it.Example: Operating cash flow €120m, group profit €100m → 1.20x.More in the Academy: Lesson earnings quality
1.52x
0.81.0
backed from 1.0 · 3 years: 1.60x
Interest coverageInterest coverageOperating income divided by interest expense: how many times the core business earns its interest. From 5x we count interest as well covered, below 2x as thinly covered.Example: Operating income €50m, interest expense €5m → 10.0x.More in the Academy: Lesson earnings quality
9.0x
25
well covered from 5 · 3 years: 8.1x
Tax rateTax rateIncome taxes divided by profit before tax, in percent. If the SEC data lack it, we approximate it as group profit plus taxes; minority interests, discontinued operations, one-off items and tax credits can shift the rate.Example: Taxes €21m, net income €79m → 21 : 100 = 21%.More in the Academy: Lesson earnings quality
How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.
Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.
As of fiscal year 2026 · Source: SEC filings
How even were the last years?
Consistency
In 10 fiscal years no loss year and 2 years with lower revenue.
Loss yearsLoss yearsFiscal years that ended with a loss on the bottom line (net income below zero). Few loss years over a long period show how evenly a company has earned so far – they say nothing about the future.Example: Loss only in fiscal year 2020 → 1 of 10.More in the Academy: Lesson revenue, profit and margin
0 of 10
net income below zero
Years with lower revenueYear with lower revenueA fiscal year in which revenue was lower than in the prior year. Only years for which the prior year’s revenue is also reported are counted.Example: Revenue 100 → €96m → one year with lower revenue.More in the Academy: Lesson revenue, profit and margin
2 of 10
revenue below the prior year
Net margin rangeNet margin rangeHighest minus lowest net margin of the fiscal years shown, in percentage points. A small range means the share of profit in revenue stayed similar over the years.Example: Net margins between 18.2% and 26.4% → range 8.2 percentage points.More in the Academy: Lesson revenue, profit and margin
6.2 percentage points
from 10.4% to 16.6%
▾▾20172026Net margin by fiscal year · ▾ revenue below the prior yearMore depth
By fiscal year
FY
Revenue vs. prior year
Net margin
2026
+8.4%
13.2%
2025
+3.6%
13.9%
2024
+3.6%
11.4%
2023
−1.4%
12.0%
2022
+5.2%
15.9%
2021
+4.2%
12.0%
2020
−5.4%
16.6%
2019
+2.0%
15.2%
2018
+0.8%
10.4%
2017
+3.0%
13.6%
Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.
As of fiscal years 2017–2026 · Source: SEC filings
Since when has today’s status held?
Check status by fiscal year
Check status by fiscal yearPoints of the four quality checks without price data by fiscal year: earlier years recalculated as of the filing date of their annual report with the figures known then, the latest year with today’s status. This shows since when today’s status has held.Example: Quality 7 of 8 in the annual reports 2022 to 2025, still 6 of 8 in 2021 → since fiscal year 2022.More in the Academy: Guide fundamental analysis
Quality: 7 of 8 criteria in every annual report since 2022 (the look-back goes no further); changed from the prior year: Growth and Financial strength.
Quality7 of 8in every annual report since 2022
Growth5 of 7since FY 2026 · before that 3 of 7
Dividend6 of 7in every annual report since 2022
Financial strength6 of 6since FY 2026 · before that 5 of 6
More depth
Criteria met by fiscal year (met/with data)
Check
2022
2023
2024
2025
2026
Quality
7/8
7/8
7/8
7/8
7/8
Growth
3/6
1/7
2/7
3/7
5/7
Dividend
6/7
6/7
6/7
6/7
6/7
Financial strength
6/6
5/6
5/6
5/6
6/6
Fiscal year 2026 with today’s status of the checks without price data (for accounts, the badges above also count P/E/PEG and dividend yield).
Earlier years as of the filing date of their annual report: FY 2025 on Jun 20, 2025, FY 2024 on Jun 20, 2024, FY 2023 on Jun 22, 2023, FY 2022 on Jun 23, 2022.
Recalculated only with SEC filings up to the respective filing date – later corrections are left out. Without price-based criteria (P/E, dividend yield); criteria without data do not count.
As of annual reports 2022–2026 · Source: SEC filings
Figures over time
Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.
Money flow in fiscal year 2026
Of 100 USD of revenue, 65.0 USD gross profit, 17.8 USD operating income and 13.2 USD net income remained.
2017Fiscal year 2017: Operating cash flow 6.9B USD · Capital expenditure 1.3B USD · Free cash flow 5.6B USD
2018Fiscal year 2018: Operating cash flow 4.7B USD · Capital expenditure 1.1B USD · Free cash flow 3.6B USD
2019Fiscal year 2019: Operating cash flow 7.0B USD · Capital expenditure 1.1B USD · Free cash flow 5.9B USD
2020Fiscal year 2020: Operating cash flow 7.2B USD · Capital expenditure 1.2B USD · Free cash flow 6.0B USD
2021Fiscal year 2021: Operating cash flow 6.2B USD · Capital expenditure 1.4B USD · Free cash flow 4.9B USD
2022Fiscal year 2022: Operating cash flow 7.3B USD · Capital expenditure 1.4B USD · Free cash flow 6.0B USD
2023Fiscal year 2023: Operating cash flow 6.0B USD · Capital expenditure 1.5B USD · Free cash flow 4.6B USD
2024Fiscal year 2024: Operating cash flow 6.8B USD · Capital expenditure 1.6B USD · Free cash flow 5.2B USD
2025Fiscal year 2025: Operating cash flow 7.0B USD · Capital expenditure 1.9B USD · Free cash flow 5.2B USD
2026Fiscal year 2026: Operating cash flow 7.3B USD · Capital expenditure 1.9B USD · Free cash flow 5.4B USD
Share count
The share count fell in 5 years by 4.9% (mostly through share repurchases).
Diluted share count
0500M1B1.5B
2017Fiscal year 2017: Diluted share count 1.4B
2018Fiscal year 2018: Diluted share count 1.4B
2019Fiscal year 2019: Diluted share count 1.4B
2020Fiscal year 2020: Diluted share count 1.4B
2021Fiscal year 2021: Diluted share count 1.4B
2022Fiscal year 2022: Diluted share count 1.4B
2023Fiscal year 2023: Diluted share count 1.3B
2024Fiscal year 2024: Diluted share count 1.3B
2025Fiscal year 2025: Diluted share count 1.3B
2026Fiscal year 2026: Diluted share count 1.3B
From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.
Metrics chart
Metrics chartUp to three metrics stacked, each with its own axis, over the same fiscal years. Optionally a second stock (dashed or hatched) and today’s sector median as a mark in the latest year – we do not have earlier medians.Example: Revenue rises, net margin falls, share count falls → more business, less profit per unit of revenue, fewer shares (mostly through buybacks).More in the Academy: Guide fundamental analysis
Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.
Dividend per share
The dividend per share rose in 5 years from 2.32 USD to 2.84 USD.
MDTUSD per share
01.002.003.00
2017Fiscal year 2017: MDT 1.72 USD
2018Fiscal year 2018: MDT 1.84 USD
2019Fiscal year 2019: MDT 2.00 USD
2020Fiscal year 2020: MDT 2.16 USD
2021Fiscal year 2021: MDT 2.32 USD
2022Fiscal year 2022: MDT 2.52 USD
2023Fiscal year 2023: MDT 2.72 USD
2024Fiscal year 2024: MDT 2.76 USD
2025Fiscal year 2025: MDT 2.80 USD
2026Fiscal year 2026: MDT 2.84 USD
Payout ratio (earnings)
The payout ratio fell in 5 years from 87.2% to 76.1%.
MDT
0%25%50%75%100%
2017Fiscal year 2017: MDT 59.5%
2018Fiscal year 2018: MDT 81.1%
2019Fiscal year 2019: MDT 58.7%
2020Fiscal year 2020: MDT 61.0%
2021Fiscal year 2021: MDT 87.2%
2022Fiscal year 2022: MDT 67.6%
2023Fiscal year 2023: MDT 96.5%
2024Fiscal year 2024: MDT 100.0%
2025Fiscal year 2025: MDT 77.6%
2026Fiscal year 2026: MDT 76.1%
Payout ratio (free cash flow)
The payout ratio (free cash flow) rose in 5 years from 63.9% to 67.1%.
MDT
0%20%40%60%80%
2017Fiscal year 2017: MDT 42.2%
2018Fiscal year 2018: MDT 69.0%
2019Fiscal year 2019: MDT 45.9%
2020Fiscal year 2020: MDT 48.1%
2021Fiscal year 2021: MDT 63.9%
2022Fiscal year 2022: MDT 56.6%
2023Fiscal year 2023: MDT 79.0%
2024Fiscal year 2024: MDT 70.5%
2025Fiscal year 2025: MDT 69.2%
2026Fiscal year 2026: MDT 67.1%
Source: SEC filings, fiscal years up to Apr 24, 2026. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.
How reliable is the dividend?
Dividend at a glance
The dividend per share was never cut as far as our annual data goes (10 years in a row); free cash flow per share covers it 1.5x.
Years without a cutYears without a dividend cutHow many fiscal years in a row up to the latest the dividend per share has not fallen, adjusted for stock splits. Only 1% less than the year before counts as a cut, a special dividend in the prior year does not. If the run reaches the start of our data, “at least” is shown.Example: Dividend 1.10 – 0.90 – 0.95 – 1.00 – 1.05 € → 3 years without a cut since the cut.More in the Academy: Lesson debt, dividends and growth
at least 10
as far as the data goes
Growth per year (5 yrs)Dividend growthHow much the dividend per share has risen on average per year, calculated over 5 fiscal years. Only for companies that paid a dividend in the last fiscal year.Example: Dividend €1.00 five years ago, €1.40 today → 7.0% per year.More in the Academy: Lesson debt, dividends and growth
+4.1%
dividend per share, average per year
Coverage by free cash flowDividend coverage by free cash flowFree cash flow per share divided by dividend per share. From 1x, the cash freely available in a year covers the dividend; below that, the company pays out more than is left over. We do not calculate it for the financial sector.Example: Free cash flow €3.00 per share, dividend €2.00 → 1.5x.More in the Academy: Lesson debt, dividends and growth
1.5x
1
covered from 1.0x
You can see the dividend yield and shareholder yield (based on the price) with a free account.Sign up free
More depth
Calculation
Dividend per share: fiscal year 2021 2.32 USD → fiscal year 2026 2.84 USD = +4.1% per year
Free cash flow per share 4.21 USD ÷ dividend per share 2.84 USD = 1.5x
Years without a cut: in a row up to fiscal year 2026, dividend per share according to the SEC, adjusted for stock splits; only 1% less than the year before counts as a cut, also for variable dividends; a special dividend in the prior year does not. If the dividend per share falls while the total paid rises, the run ends as “unclear”. “At least” is shown only if our data ends earlier.
Shareholder yield: dividends paid plus share repurchases minus proceeds from new shares according to the cash flow statement of the last fiscal year, divided by today’s market value. Missing repurchases or new shares count as 0; without reported dividend or repurchase payments (among others for many stocks of the extended selection) there is no value. Describes the reported figures – not investment advice.
Valuation against its own historyWhere P/E, P/S or price/free cash flow stands today compared with the median of the company’s own last 5 fiscal years, in percent. Up to 10% deviation counts as “about at the median”. Describes only the position, not a judgement on an appropriate price.Example: P/E today 22, own 5-year median 27 → 22 ÷ 27 − 1 = −18.5%, so below the median.More in the Academy: Lesson cheaper or pricier than usual?
The P/E is about at its own median of the 5 fiscal years before.
With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation.Sign up free
Source: SEC filings and our daily candles
Dividends and share repurchases
How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.
Dividend per share
2.84USD · Fiscal year 2026
Dividend growth per year
3 y+1.4%5 y+4.1%10 y+6.5%
Payout ratio
of earnings76%of free cash flow67%
To shareholders (5 years)
27.5B USD35% through repurchases
Share count over 5 years
−4.9%fewer shares – each share is a larger stake
Dividend per share
The dividend per share rose in 5 years from 2.32 USD to 2.84 USD.
Dividend per shareUSD per sharePer share as filed with the SEC, including special dividends; obvious filing errors are hidden.
01.002.003.00
2017Fiscal year 2017: Dividend per share 1.72 USD
2018Fiscal year 2018: Dividend per share 1.84 USD
2019Fiscal year 2019: Dividend per share 2.00 USD
2020Fiscal year 2020: Dividend per share 2.16 USD
2021Fiscal year 2021: Dividend per share 2.32 USD
2022Fiscal year 2022: Dividend per share 2.52 USD
2023Fiscal year 2023: Dividend per share 2.72 USD
2024Fiscal year 2024: Dividend per share 2.76 USD
2025Fiscal year 2025: Dividend per share 2.80 USD
2026Fiscal year 2026: Dividend per share 2.84 USD
Payout ratios
The payout ratio fell in 5 years from 87.2% to 76.1%.
Payout ratio (earnings)Payout ratio (free cash flow)
0%25%50%75%100%
2017Fiscal year 2017: Payout ratio (earnings) 59.5% · Payout ratio (free cash flow) 42.2%
2018Fiscal year 2018: Payout ratio (earnings) 81.1% · Payout ratio (free cash flow) 69.0%
2019Fiscal year 2019: Payout ratio (earnings) 58.7% · Payout ratio (free cash flow) 45.9%
2020Fiscal year 2020: Payout ratio (earnings) 61.0% · Payout ratio (free cash flow) 48.1%
2021Fiscal year 2021: Payout ratio (earnings) 87.2% · Payout ratio (free cash flow) 63.9%
2022Fiscal year 2022: Payout ratio (earnings) 67.6% · Payout ratio (free cash flow) 56.6%
2023Fiscal year 2023: Payout ratio (earnings) 96.5% · Payout ratio (free cash flow) 79.0%
2024Fiscal year 2024: Payout ratio (earnings) 100.0% · Payout ratio (free cash flow) 70.5%
2025Fiscal year 2025: Payout ratio (earnings) 77.6% · Payout ratio (free cash flow) 69.2%
2026Fiscal year 2026: Payout ratio (earnings) 76.1% · Payout ratio (free cash flow) 67.1%
What goes back to shareholders
Over 5 years, 27.5B USD went back to shareholders, 35% of it through share repurchases. That is 104% of the free cash flow of those years. This was offset by new shares issued for 1.3B USD (including employee plans).
Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.
Valuation over time
Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.Log in
Sector comparison
Medtronic next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.
Sector comparison MDT, sector Health Care; last row: sector median
Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.
Key figures with traffic lights
Each light follows a simple, disclosed rule. The comparison is with the sector median Sector medianThe middle value of all companies in a sector: half are above it, half below. Unlike the average, single outliers hardly distort it.Example: Margins 4%, 8%, 10%, 12%, 60% → median 10%, average 18.8%.More in the Academy: Lesson putting the P/E in context of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).
Revenue growth
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light yellow: below sector
+3.8%per year, last 5 years
Sector Health Care: median +8.5% (25 symbols)
What does this mean? Revenue: over 5 years it grew by 3.8% per year on average, but more slowly than the median company in the sector (+8.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
Net income (total)
Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth
Light green: above sector
+5.9%per year, last 5 years
Sector Health Care: median +5.5% (20 symbols)
per share: +7.0% per year (5 years, split-adjusted)
What does this mean? Total net income: over 5 years it grew by 5.9% per year on average – at least as fast as the median company in the sector (+5.5%).
Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.
What does this mean? Of every 100 USD in revenue, 13.20 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 12.0%.
Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.
Debt / equity
Debt-to-equity ratioFinancial debt (loans, bonds) divided by equity. A high value amplifies good and bad years alike. The key figures bar in the chart only uses long-term financial debt.Example: Financial debt €300m, equity €500m → 0.6.More in the Academy: Lesson debt, dividends and growth
Light green: lower than sector
0.51latest balance sheet
Sector Health Care: median 0.66 (19 symbols)
What does this mean? For every 1 USD of equity there is 0.51 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.
Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.
Payout ratio
Payout ratioThe share of profit that a company pays out as a dividend. Above 100% it pays out more than it earns.Example: Dividend €1, earnings per share €2.50 → payout ratio 40%.More in the Academy: Lesson debt, dividends and growth
Light yellow: high
76%Dividend / earnings per share
Sector Health Care: median 56% (16 symbols)
What does this mean? Of every 1 USD of earnings per share, 0.76 USD went to shareholders as a dividend. Little buffer remains for weaker years. Median company in the sector: 56%.
Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.
Profitable years
Profitable yearsHow many of the last fiscal years ended with a profit rather than a loss on the bottom line. The figure shows how consistently a company earns.Example: Profit in 9 of 10 years → one loss year.More in the Academy: Lesson revenue, profit and margin
Light green: profit every year
10 of 10fiscal years with a profit
What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.
Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).
Last fiscal year and 13F
Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
36.4B USD
Revenue vs. prior year
+8.4%
Net income (FY)
4.8B USD
Net income vs. prior year
+3.0%
EPS (FY)
3.73 USD
Superinvestors holding
3 of 26
Fiscal year to Apr 24, 2026 · 10-K filed Jun 18, 2026 · Balance sheet Jul 31, 2026 (filed Sep 3, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term).Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
Year
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
2026
Apr 24, 2026
36.4B
4.8B
13.2%
3.73
2.84
76%
2025
Apr 25, 2025
33.5B
4.7B
13.9%
3.61
2.80
78%
2024
Apr 26, 2024
32.4B
3.7B
11.4%
2.76
2.76
100%
2023
Apr 28, 2023
31.2B
3.8B
12.0%
2.82
2.72
96%
2022
Apr 29, 2022
31.7B
5.0B
15.9%
3.73
2.52
68%
2021
Apr 30, 2021
30.1B
3.6B
12.0%
2.66
2.32
87%
2020
Apr 24, 2020
28.9B
4.8B
16.6%
3.54
2.16
61%
2019
Apr 26, 2019
30.6B
4.6B
15.2%
3.41
2.00
59%
2018
Apr 27, 2018
30.0B
3.1B
10.4%
2.27
1.84
81%
2017
Apr 28, 2017
29.7B
4.0B
13.6%
2.89
1.72
60%
Quarters (amounts in USD, per share in USD)
Quarter
End
Revenue
Net income
Margin
Earnings per share
Dividend per share
Payout
Q3/26
Jul 31, 2026
9.8B
1.5B
15.1%
1.14
0.72
63%
Q2/26*
Apr 24, 2026
9.8B
1.2B
12.7%
–
–
–
Q1/26
Jan 23, 2026
9.0B
1.1B
12.7%
0.89
0.71
80%
Q4/25
Oct 24, 2025
9.0B
1.4B
15.3%
1.07
0.71
66%
Q3/25
Jul 25, 2025
8.6B
1.0B
12.1%
0.81
0.71
88%
Q2/25*
Apr 25, 2025
8.9B
1.1B
11.8%
–
–
–
Q1/25
Jan 24, 2025
8.3B
1.3B
15.6%
1.01
0.70
69%
Q4/24
Oct 25, 2024
8.4B
1.3B
15.1%
0.99
0.70
71%
Q3/24
Jul 26, 2024
7.9B
1.0B
13.2%
0.80
0.70
88%
Q2/24*
Apr 26, 2024
8.6B
654.0M
7.6%
–
–
–
Q1/24
Jan 26, 2024
8.1B
1.3B
16.3%
0.99
0.69
70%
Q4/23
Oct 27, 2023
8.0B
909.0M
11.4%
0.68
0.69
101%
* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.
How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year Growth per year (CAGR)The average annual growth rate over several years, as if the value had grown equally strongly every year. Individual good or bad years even out in it.Example: Revenue €100m → €161m in 5 years → (161 ÷ 100) to the power of 1/5 − 1 = 10% per year.More in the Academy: Lesson debt, dividends and growth over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.
Information only – does not affect the other analysis methods, not investment advice.
Insiders
Insider transactionsExecutives, directors and major shareholders (over 10%) of US companies report their own transactions in their company’s stock to the SEC within two business days (Form 4). Purchases in the market count as more meaningful than sales (often taxes, estate planning).Example: Three executives acquire stock worth a total of 2 million USD within two weeks → “purchases by several insiders”.More in the Academy: Glossary
Jul 8, 2026Walter Matthew R.OfficerOpen-market sale · 10b5-1 plan3,102 shares · $257.9K · SEC
Jun 8, 2026Kiil Harry SkipOfficerOpen-market sale228 shares · $18.3K · SEC
Jun 8, 2026Kiil Harry SkipOfficerOpen-market sale3,961 shares · $318.6K · SEC
Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.
Which superinvestors hold Medtronic?
Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.
Trend score +90
Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+10
Price change 60 days+15
Volatility and trend strength
ADX 14 (trend strength)pronounced (above 25)
Price change 60 daysup
ATR ATR (Average True Range)The average range per trading day over the last 14 days. It makes distances comparable, whether a stock costs 10 or 1,000.Example: ATR 2.50 at a price of 100: 0.4 ATR is 1.00, i.e. 1%.More in the Academy: Lesson ATR and moving averages as price values only when logged in.
Connected Health Devices - Global Strategic Business Report 2026: Capitalize on 21.3% CAGR and $11.6B Revenue Opportunity by 2032 with Apple, Medtronic, Microsoft, Roche and Epic SystemsYahoo Finance · Nov 19, 16:10
Global Clinical-Grade Wearables for Pharma and Biotech Market Report 2026 | Capitalize on 21.5% CAGR to $7.48B by 2030 as Abbott, Medtronic, DexCom and Philips Scale AI-Driven RPMYahoo Finance · Nov 19, 15:46